About Us

Pi Therapeutics is a preclinical-stage pharmaceutical company dedicated to the development of protein degradation modulators for the treatment of cancer. PI’s lead drug modulates pathways related to proteostasis, offering a unique approach to the preferential targeting of cancer cells. Preclinical data to date have demonstrated a compelling safety and efficacy profile which is differentiated from approved protein degradation inhibitors. The company, located in the Weizmann Science Park in Israel, was founded in 2015 based on technology in-licensed from Johns Hopkins University and has raised a total of approximately $24M to date. The company targets hematologic as well as solid tumor indications and expects to initiate clinical studies next year.

The company’s major investors are Pontifax, Global Health Sciences Fund (Quark Venture and GF Securities), Arkin Bio Ventures, Consensus Business Group (CBG), RMGP Biopharma Investment Fund.

Pi Therapeutics is a preclinical-stage pharmaceutical company dedicated to the development of protein degradation modulators for the treatment of cancer. PI’s lead drug modulates pathways related to proteostasis, offering a unique approach to the preferential targeting of cancer cells. Preclinical data to date have demonstrated a compelling safety and efficacy profile which is differentiated from approved protein degradation inhibitors. The company, located in the Weizmann Science Park in Israel, was founded in 2015 based on technology in-licensed from Johns Hopkins University and has raised a total of approximately $24M to date. The company targets hematologic as well as solid tumor indications and expects to initiate clinical studies next year.

The company’s major investors are Pontifax, Global Health Sciences Fund (Quark Venture and GF Securities), Arkin Bio Ventures, Consensus Business Group (CBG), RMGP Biopharma Investment Fund.

Read more

Management

Dr. Ori Kalid

CEO

Multidisciplinary biotech leader with over 15 years of industry experience. Dr. Kalid founded Pi therapeutics with Pontifax and led the company through a successful 3-year incubation period at the FutuRx biotech accelerator followed by series-A and series-B financing rounds. Before Pi, acted as Head of Discovery at Karyopharm Therapeutics, a clinical stage oncology company developing first in class targeted therapies, where he led the development and application of a novel multidisciplinary drug discovery platform, and contributed across various aspects of translational research. Prior to that held the position of Director of Computer-Aided Drug Discovery at EPIX (previously Predix) Pharmaceuticals, where he led multiple drug discovery programs including successful collaborations with big pharma. Ori Kalid earned a PhD in computational biology, a MSc. In biotechnology and a BA in mathematics and computer-science, all from Tel-Aviv University. Dr. Kalid is also an active member of the 8400 health network.

Read more

Uzi Izhaky

Acting CFO

Uzi Izhaky, CPA (LLB), brings over 20 years of finance experience in the innovation sector.
He is responsible for overseeing the financial management activities.
He is a qualified CPA and holds an LL.B degree from Ono Academic College.

Dr. Ori Kalid

CEO

Multidisciplinary biotech leader with over 15 years of industry experience. Dr. Kalid founded Pi therapeutics with Pontifax and led the company through a successful 3-year incubation period at the FutuRx biotech accelerator followed by series-A and series-B financing rounds. Before Pi, acted as Head of Discovery at Karyopharm Therapeutics, a clinical stage oncology company developing first in class targeted therapies, where he led the development and application of a novel multidisciplinary drug discovery platform, and contributed across various aspects of translational research. Prior to that held the position of Director of Computer-Aided Drug Discovery at EPIX (previously Predix) Pharmaceuticals, where he led multiple drug discovery programs including successful collaborations with big pharma. Ori Kalid earned a PhD in computational biology, a MSc. In biotechnology and a BA in mathematics and computer-science, all from Tel-Aviv University. Dr. Kalid is also an active member of the 8400 health network.

Pi Therapeutics is a preclinical-stage pharmaceutical company dedicated to the development of protein degradation modulators for the treatment of cancer. PI’s lead drug modulates pathways related to proteostasis, offering a unique approach to the preferential targeting of cancer cells. Preclinical data to date have demonstrated a compelling safety and efficacy profile which is differentiated from approved protein degradation inhibitors. The company, located in the Weizmann Science Park in Israel, was founded in 2015 based on technology in-licensed from Johns Hopkins University and has raised a total of approximately $24M to date. The company targets hematologic as well as solid tumor indications and expects to initiate clinical studies next year.

The company’s major investors are Pontifax, Global Health Sciences Fund (Quark Venture and GF Securities), Arkin Bio Ventures, Consensus Business Group (CBG), RMGP Biopharma Investment Fund.